Lifeline Biotechnologies, Inc.
LLBO
Other OTC0.00
USD
+0.00
- -
ISIN
US53219E8084
CUSIP
53219E808
Return %
Stock
S&P500
1Y
25.00
26.84
3Y
150.00
77.03
5Y
-82.76
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James D. Holmes
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1325 Airmotive Way Reno NV United States of America 89502
- IPO Date
- Feb 2, 1995
- Website
- lbti.co
- Similar Companies
- Business
- Lifeline Biotechnologies, Inc. (LLBO) develops and commercializes innovative medical diagnostic technologies focused on point-of-care testing for infectious diseases and critical health conditions. The company offers the ABT-7500 automated workstation, which performs nucleic acid extraction, purification, and real-time PCR amplification for detecting pathogens such as SARS-CoV-2, influenza, and other respiratory viruses; the ABT-4500 semi-automated nucleic acid extraction system for high-throughput sample preparation; and related molecular diagnostic assays and reagents for clinical laboratories and healthcare providers. These products enable rapid, accurate diagnostics with minimal hands-on time, targeting hospitals, clinics, and point-of-care settings primarily in the United States. Founded in 2010 and headquartered in Virginia Beach, Virginia, Lifeline Biotechnologies operates within the biotechnology and diagnostics industry, serving the healthcare sector with a focus on molecular diagnostics. In recent developments, the company expanded its product portfolio with enhancements to its PCR-based testing platforms to address emerging infectious disease threats as of 2025, while maintaining strategic partnerships with clinical reference labs for assay validation and distribution.